Zacks Investment Research downgraded shares of Mirna Therapeutics, Inc. (NASDAQ:SYBX) from a hold rating to a sell rating in a research note published on Wednesday morning.
According to Zacks, “Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company’s pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. “
A number of other research analysts have also recently issued reports on the company. Leerink Swann assumed coverage on Mirna Therapeutics in a report on Tuesday, September 19th. They set an outperform rating and a $25.00 price objective for the company. ValuEngine cut Mirna Therapeutics from a hold rating to a sell rating in a research note on Friday, September 1st.
Shares of Mirna Therapeutics (NASDAQ SYBX) traded up $0.24 during midday trading on Wednesday, hitting $10.01. The company’s stock had a trading volume of 4,200 shares, compared to its average volume of 11,634. Mirna Therapeutics has a 12 month low of $8.76 and a 12 month high of $23.00.
About Mirna Therapeutics
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.